节点文献

5-HT3受体拮抗剂在血液系统恶性肿瘤患者化疗止吐中的应用

The application 5-HT3 antagonist in anti-vomiting treatment for hemato-logic neoplasms chemotherapy

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 李娟罗绍凯黎军和赵莹

【Author】 LI Juan, LUO Shaokai, O Junhe,Hematologic Department of first afiliated hospital of Zhongshan Medical University, Guangzhou, 510080

【机构】 中山大学附属第一医院血液科中山大学附属第一医院血液科 广州 510080广州 510080广州 510080

【摘要】 目的 了解和比较不同的5-HT3拮抗剂的临床疗效和副作用。方法 化疗前30min用凯特瑞3mg,或用欧必亭5mg,或用奈西雅0.3mg,或用富米汀、或枢丹8mg,加生理盐水静脉推注,用药后观察恶心、呕吐等副作用。结果 凯特瑞的止吐疗效为88.92%,明显优于枢丹、富米汀、呕必亭,与奈西雅相当,在副作用方面,凯特瑞、枢丹、富米汀、呕必亭、奈西雅均未见严重副作用,凯特瑞的腹胀发生率比奈西雅、富米汀低。结论 凯特端是一种止吐效果好,作用时间持久,能较好控制急性及延迟呕吐,使用安全的理想止吐药。

【Abstract】 Objective to understand and compare the clinical curative effect and sides effect of 5-HT3 antagonist. Methods kytril 3mg or navoban 5mg or nasea 0.3mg or ondansetron 8mg was used intravenous before chemotherapy after diluted with 0.9% sodium chloride. Then evaluate the incidence of nausea, vomiting and other side effects. Results anti-vomiting efficiency of kytril was 88.92%, which was equal to nasea and obviously better than ondansetron and navoban. About side effects, none of serious side effects was observed in kytril, ondansetron, navoban and nasea treatment group. The incidence of abdominal distension in kytril treatment group was lower than that of nasea and ondansetron treatment group. Conclusion Kytril is an ideal anti-vomiting drug which is good in controlling acute or delayed vomiting. And the acting time of kytril is longer and it can be used safely.

  • 【文献出处】 实用肿瘤学杂志 ,Journal of Practical Oncology , 编辑部邮箱 ,2003年03期
  • 【分类号】R733
  • 【被引频次】10
  • 【下载频次】124
节点文献中: 

本文链接的文献网络图示:

本文的引文网络